Chemotactic nanomotor for multimodal combined therapy of glioblastoma  

作　　者：Ting Li Lin Chen Yunxin Xue Xiangyu Xiao Wenjun Dai Kaiyuan Tan Tiantian Chen Yingfang Tao Chun Mao Jian Shen Mimi Wan 

机构地区：[1]National and Local Joint Engineering Research Center of Biomedical Functional Materials,School of Chemistry and Materials Science,Nanjing Normal University,Nanjing 210023,China

出　　处：《Science China Chemistry》2024年第4期1277-1288,共12页中国科学（化学英文版）

基　　金：supported by the National Natural Science Foundation of China(22175096,22275095);the Social Development Project of Jiangsu Natural Science Foundation(BE2019744);the Qinglan Project Foundation of Colleges and Universities of Jiangsu Province;the Jiangsu Collaborative Innovation Center of Biomedical Functional Materials;the Priority Academic Program Development of Jiangsu Higher Education Institution;the Postgraduate Research&Practice Innovation Program of Jiangsu Province(KYCX22_1545)。

摘　　要：Glioblastoma(GBM) is the most aggressive malignant brain tumor. Due to the infiltration and heterogeneity of GBM, the obstruction of the blood-brain barrier(BBB) and the unique immunosuppressive mechanism, it is hard to achieve significant effects of GBM treatment. Here, a kind of chemotactic nanomotor that loaded with glucose oxidase(GOx) and carboxylated cisplatin(Pt(IV)) prodrug on the L-arginine-derived polymer is proposed. The nanomotors are driven by catalysis of glucose decomposition and the positive chemotaxis towards the GBM microenvironment where inducible nitric oxide synthase and reactive oxygen species are highly expressed. This facilitates the BBB crossing and GBM targeting of the nanomotors. In addition, the released nitric oxide(NO) during propulsion as well as the loaded GOx and Pt(IV) can exert combined NO/starvation/chemotherapy. Meanwhile, it is able to induce and enhance the immune response through multiple pathways, thus better coping with the complexities of GBM treatment.

关 键 词：CHEMOTAXIS combined therapy GLIOBLASTOMA NANOMOTORS 

分 类 号：R739.4[医药卫生—肿瘤] TB383.1[医药卫生—临床医学]